For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it develops a new generation of drugs, and this pattern has continued as it sold its Arimidex a
AstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Sankyo for an experimental breast cancer drug – and so far it looks like money w
Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen
